Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Sturchler and Wrynn explain why their job-sharing experience was one of the most successful and energizing periods of their careers.

Canavan describes how flexible working positively impacts his team.

Our Global Head of Talent Acquisition & Staffing talks about ongoing recruitment efforts to create a more diverse and inclusive organization.

In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.

Novartis works tirelessly with third-party organizations to improve access to cancer care.

Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.